Mar 14 2023 44 mins
Antibody-drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. However, unlike chemotherapy, ADCs are intended to directly target and kill tumor cells while, at the same time sparing normal, healthy cells.
Antibody-drug conjugates consist of three parts:
Today, antibody-drug conjugates have widespread treatment potential in obcology and hematology, and beyond. However, safe manufacturing of these highly potent drugs requires also requires a highly skilled capable team of experts in well-controlled manufacturing facilities.
In this episode of the Onco’Zine Brief, produced in collaboration with ADC Review | Journal of Antibody-drug Conjugates, Peter Hofland talks with Dr. Matthias Bucerius.
Dr. Bucerius is Vice President and General Manager at MilliporeSigma. He is responsible for Contract Development and Manufacturing Organsation (CDMO) business of the company, leading a fully integrated global team with Manufacturing Operations, Commercial, Marketing & Strategy, Technology & Innovation organizations.
The company is helping its clients in developing and manufacturing a variety of products, including antibody-drug conjugates.
Antibody-drug conjugates or ADCs are targeted therapies that have opened new ways in targeting diseases like cancer and hematological malignancies.
What is unique about ADCs is that they leverage the specific targetability benefits offered by antibodies and combine that with the high potency of small-molecule drugs. This combination makes these agents uniquely targetable therapies. And unlike traditional chemotherapy, these ADCs target tumors by delivering the attached payload to destroy cancer cells while sparing the healthy or normal cells, thereby potentially reducing negative side effects for patients.
About The Onco'Zine Brief
The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.
For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, Download our Media Kit, or visit our Patreon page.
For more information about cancer and cancer treatments, visit our online journal Onco'Zine.
The Onco’Zine Brief is made possible, in part, by Java Original Coffee – the home of artisan roasted coffee and Roastmasterz by Java Original.
Become a supporter of this podcast: https://www.spreaker.com/podcast/the-onco-zine-brief--2786156/support.
Antibody-drug conjugates consist of three parts:
- an antibody specific to the target associated antigen,
- a payload (sometimes calles a warhead) designed to kill target cancer cells, and
- a chemical linker specifically designed to attach or link the payload to the antibody.
Today, antibody-drug conjugates have widespread treatment potential in obcology and hematology, and beyond. However, safe manufacturing of these highly potent drugs requires also requires a highly skilled capable team of experts in well-controlled manufacturing facilities.
In this episode of the Onco’Zine Brief, produced in collaboration with ADC Review | Journal of Antibody-drug Conjugates, Peter Hofland talks with Dr. Matthias Bucerius.
Dr. Bucerius is Vice President and General Manager at MilliporeSigma. He is responsible for Contract Development and Manufacturing Organsation (CDMO) business of the company, leading a fully integrated global team with Manufacturing Operations, Commercial, Marketing & Strategy, Technology & Innovation organizations.
The company is helping its clients in developing and manufacturing a variety of products, including antibody-drug conjugates.
Antibody-drug conjugates or ADCs are targeted therapies that have opened new ways in targeting diseases like cancer and hematological malignancies.
What is unique about ADCs is that they leverage the specific targetability benefits offered by antibodies and combine that with the high potency of small-molecule drugs. This combination makes these agents uniquely targetable therapies. And unlike traditional chemotherapy, these ADCs target tumors by delivering the attached payload to destroy cancer cells while sparing the healthy or normal cells, thereby potentially reducing negative side effects for patients.
About The Onco'Zine Brief
The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.
For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, Download our Media Kit, or visit our Patreon page.
For more information about cancer and cancer treatments, visit our online journal Onco'Zine.
- To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.
The Onco’Zine Brief is made possible, in part, by Java Original Coffee – the home of artisan roasted coffee and Roastmasterz by Java Original.
Become a supporter of this podcast: https://www.spreaker.com/podcast/the-onco-zine-brief--2786156/support.